Elevation Oncology Inc

NASDAQ:ELEV  
1.49
0.00 (0.00%)
Products

Elevation Oncology Announces FDA Fast Track Designation Granted To Seribantumab For Tumor-Agnostic Treatment Of Solid Tumors Harboring NRG1 Gene Fusions

Published: 05/25/2022 11:39 GMT
Elevation Oncology Inc (ELEV) - Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-agnostic Treatment of Solid Tumors Harboring Nrg1 Gene Fusions.